Results 151 to 159 of about 4,513 (159)

Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for grade 2 or higher emesis. [PDF]

Medicine (Baltimore)
Na J, Kim JJ, Oh SB, Park K.
europepmc   +1 more source

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database. [PDF]

Front Pharmacol
Yang C, Xu P, Wu T, Fan Y, Li Q, Zhang J, Shen X, Dong X.   +7 more
europepmc   +1 more source

Comparative Efficacy of Novel Versus Traditional Antiemetic Agents in Preventing Chemotherapy-Induced Nausea and Vomiting With Moderate or Highly Emetogenic Chemotherapy: A Systematic Review. [PDF]

Cureus
Nashed SM, Morcos RKA, Atif M, Shehryar A, Rehman A, Kumari R, Khan SM, Hassan W, Zeb MR, Zia TA, Jameel S.   +10 more
europepmc   +1 more source

Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights. [PDF]

Support Care Cancer
Pieniążek M, Polakiewicz-Gilowska A, Kubeczko M, Las-Jankowska M, Pacholczak-Madej R, Kilian-Van Miegem P, Ziobro M, Łacko A, Jarząb M, Püsküllüoğlu M.   +9 more
europepmc   +1 more source

Prior Authorization, Quantity Limits, and Step Therapy for Patient-Administered Antiemetics.

JAMA Netw Open
Vu K, Gupta A, Chino F, Barnes J, Thom B, Kyle MA.   +5 more
europepmc   +1 more source